CRITERIA FOR THE CHOICE AND DEFINITION OF HEALTHY-VOLUNTEERS AND OR PATIENTS FOR PHASE-I AND PHASE-II STUDIES IN DRUG DEVELOPMENT - COMMENTARY ON AN ACTION FOR COOPERATIVE RESEARCH

被引：5
|
作者：
BECHTEL, PR [1 ]
ALVAN, G [1 ]
机构：
[1] HUDDINGE HOSP,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1989年 / 36卷 / 06期
关键词：
D O I：
10.1007/BF00637733
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：549 / 550
页数：2
相关论文
共 17 条
  • [1] CHARACTERISTICS OF VOLUNTEERS WHO PARTICIPATE IN PHASE-I AND PHASE-II DRUG DEVELOPMENT STUDIES
    DEVRIES, B
    HUGHES, GS
    FRANCOM, SF
    CLINICAL RESEARCH, 1988, 36 (03): : A362 - A362
  • [2] SELECTION OF HEALTHY-VOLUNTEERS FOR PHASE-I STUDIES
    SIBILLE, M
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 : S167 - S176
  • [3] CLINICAL DEVELOPMENT OF NAFARELIN ACETATE - PHASE-I AND PHASE-II STUDIES
    HOFFMAN, PG
    HENZL, MR
    CHAPLIN, MD
    NERENBERG, CA
    JOURNAL OF ANDROLOGY, 1987, 8 (01): : S17 - S22
  • [4] CRITICAL LIMIT OF BILIRUBIN CONCENTRATION FOR SELECTION OF HEALTHY-VOLUNTEERS TO PHASE-I STUDIES
    OLAGNIER, V
    SIBILLE, M
    DURAND, DV
    DEIGAT, N
    BALTASSAT, P
    LEVRAT, R
    THERAPIE, 1993, 48 (06): : 617 - 622
  • [5] PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS IN PHASE-I PHASE-II OF DRUG DEVELOPMENT
    VANPEER, A
    SNOECK, E
    HUANG, ML
    HEYKANTS, J
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) : 49 - 59
  • [6] DEVELOPMENT OF DRUG-METABOLIZING-ENZYMES (PHASE-I AND PHASE-II) - TENTATIVE ROLE IN TERATOGENESIS
    RANE, A
    PACIFIC, GM
    GUTHENBERG, C
    MANNERVIK, B
    WARHOLM, M
    TERATOLOGY, 1986, 33 (02) : A46 - A46
  • [7] PHASE-I AND PRELIMINARY PHASE-II STUDIES ON ACLACINOMYCIN-A IN PATIENTS WITH ACUTE-LEUKEMIA
    SUZUKI, H
    KAWASHIMA, K
    YAMADA, K
    MINAMI, S
    KATO, Y
    TANIMOTO, M
    YAMADA, H
    ISOBE, K
    HAYASHI, K
    YAMAGUCHI, H
    TAKAMATSU, J
    WATANABE, E
    KODERA, Y
    SHIKU, H
    KAMIYA, T
    OHNO, R
    MORISHITA, H
    YOKOMAKU, S
    YOSHIDA, K
    OGURA, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1980, 10 (01) : 111 - 117
  • [8] PHARMACODYNAMICS OF THE GPIIB-IIIA ANTAGONIST INTEGRELIN - PHASE-I CLINICAL-STUDIES IN NORMAL HEALTHY-VOLUNTEERS
    CHARO, IF
    SCARBOROUGH, RM
    DUMEE, CP
    WOLF, D
    PHILLIPS, DR
    SWIFT, RL
    CIRCULATION, 1992, 86 (04) : 260 - 260
  • [9] THE PLACEBO-EFFECT IN HEALTHY-VOLUNTEERS - INFLUENCE OF EXPERIMENTAL CONDITIONS ON THE ADVERSE EVENTS PROFILE DURING PHASE-I STUDIES
    ROSENZWEIG, P
    BROHIER, S
    ZIPFEL, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (05) : 578 - 583
  • [10] THE PLACEBO-EFFECT IN HEALTHY-VOLUNTEERS - INFLUENCE OF EXPERIMENTAL CONDITIONS ON PHYSIOLOGICAL-PARAMETERS DURING PHASE-I STUDIES
    ROSENZWEIG, P
    BROHIER, S
    ZIPFEL, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (06) : 657 - 664
12